Evidence map›Paper›PMID 31165975›Full record

ArticleRadiological physics and technology2019

The feasibility of contrast-enhanced spectral mammography immediately after contrast-enhanced CT.

Nobuko Okada, Fuminari Tatsugami, Mai Sugai, Izumi Okita, Mitsuya Ito, Shoichiro Ohtani, Kouichi Ichimura, Masaki Urashima, Kazuo Awai

Abstract read
PubMed Publisher
In one paragraph

Article in Radiological physics and technology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nobuko OkadaDepartment of Radiology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan. okadano22@outlook.jp.
Fuminari TatsugamiDepartment of Diagnostic Radiology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Mai SugaiDepartment of Radiology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan.
Izumi OkitaDepartment of Radiology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan.
Mitsuya ItoDepartment of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan.
Shoichiro OhtaniDepartment of Breast Surgery, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan.
Kouichi IchimuraDepartment of Pathology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan.
Masaki UrashimaDepartment of Diagnostic Radiology, Hiroshima City Hiroshima Citizens Hospital, 33-7 Motomachi, Naka-ku, Hiroshima, 730-8518, Japan.
Kazuo AwaiDepartment of Diagnostic Radiology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan.
Hiroshima City Asa Citizens Hospital · JPHiroshima University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Contrast-enhanced spectral mammography (CESM) is a digital mammography method that requires an intravenous injection of iodinated contrast material to detect hypervascular lesions. In patients undergoing evaluation for metastases before breast tumor surgery, a contrast material must be injected for computed tomography (CT) and CESM studies. The purpose of our study was to investigate the feasibility of performing CESM immediately after contrast-enhanced CT, without injecting additional contrast material. We enrolled 77 women with 88 breast carcinomas. Immediately after contrast-enhanced CT, we performed CESM without injecting additional contrast material. The patients were divided into two groups based on the length of the interval between contrast material injection and the start of mammography. In group A (n = 51), it was less, and in group B (n = 26) it was more than 7 min. We measured the tumor gland contrast of each tumor on the CESM images and recorded the tumor opacification on a 4-point visual scale. The mean interval between the start of contrast material injection for CT and the acquisition of mammograms in groups A and B was 5.41 and 10.40 min, respectively. All lesions were detectable on the CESM images. There was no significant difference in the visual evaluation between the two groups (p = 0.21). CESM immediately after contrast-enhanced CT without the injection of additional contrast material is feasible and cost-effective.

Indexed as

Contrast MediaMammographyTomography, X-Ray ComputedAdultAgedAged, 80 and overFeasibility StudiesFemaleHumansInjectionsMiddle AgedRetrospective StudiesTime FactorsContrast MediaContrast-enhanced computed tomographyContrast-enhanced spectral mammographyDigital mammographyIodinated contrast

Identifiers

PMID31165975
OpenAlexW2959625394

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.